ALN-AT3 Global License TermsGlobal License Terms • May 4th, 2018 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THESE ALN-AT3 GLOBAL LICENSE TERMS (this “Agreement”) are entered into as of January 6, 2018 (the “Execution Date”), by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”). Except where otherwise specifically provided herein, the rights and obligations set forth herein shall only become binding upon the Effective Date (which, when used in this Agreement, has the meaning provided in Amendment No. 2 (as defined herein)).
ConfidentialGlobal License Terms • August 6th, 2019 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THESE AMENDED AND RESTATED ALN-AT3 GLOBAL LICENSE TERMS (this “Agreement”) are entered into as of April 8, 2019 (the “A&R Execution Date”), by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”). Except where otherwise specifically provided herein, the amendments to the rights and obligations in the Original Agreement that are set forth herein shall only become binding upon the Effective Date (as defined below).
